Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2008
10/02/2008US20080241258 Treatment of diseases with nanoparticles having a size-dependent cytotoxicity
10/02/2008US20080241257 Biodegradable Nanoparticles Incorporating Highly Hydrophilic Positively Charged Drugs
10/02/2008US20080241256 Targeted active agent delivery system based on calcium phosphate nanoparticles
10/02/2008US20080241255 Enhanced inhalation delivery to lungs; effective for wide range of medicants
10/02/2008US20080241254 Having d90 value range of 4-15 mu m; bioavailable oral suspension formulations; reducing gastrointestinal tract side effects; antiprotozoal agents
10/02/2008US20080241253 Formulations for Spray-Drying Large Porous Particles
10/02/2008US20080241252 Methods and compositions for intraocular administration to treat ocular conditions
10/02/2008US20080241251 Method of Producing Microparticles
10/02/2008US20080241250 In vivo bioreactors and methods of making and using same
10/02/2008US20080241249 Cyanoacrylate composite
10/02/2008US20080241248 Porous Matrix
10/02/2008US20080241246 Cell-based therapies for treating liver disease
10/02/2008US20080241245 Biodegradable, disposable fibrillar collagen matrix; such as bupivacaine contained in sponge; extended time postoperative pain management
10/02/2008US20080241244 Combining with such as potassium phosphate buffer solution containing sucrose, gelatin and ethylene oxide-propylene oxide copolymer; cooling, expanding then evaporation or sublimation drying; shelf life
10/02/2008US20080241243 Biodegradable fibrillar collagen matrix; sustained release; postsurgery pain control
10/02/2008US20080241242 Porous Polyelectrolyte Materials
10/02/2008US20080241241 Administering controlled release formulations utilizing slow and fast dissolving carriers; reducing side effects
10/02/2008US20080241240 Dihydropyridine derivative delayed and statin rapid release components; preventing antagonistic and other adverse side effects; atherosclerosis, hypertension; dosage kits
10/02/2008US20080241239 Pharmaceutical Tablets Having a Separation Mark Positioned on the Side of Said Tablets
10/02/2008US20080241238 Layered core contains active ingredient layer, a swellable compressed layer, and an excipient layer that is insoluble in gastric fluids; outer film attached to swellable layer to form rupturing system that ruptures when intestine is reached; pharmacokinetics
10/02/2008US20080241237 Taste-masked microparticles of hydroxyzine, cetirizine (hydrochloride), efletirizine, meclizine, buclizine or levocetirizine dihydrochloride coated with a taste-masking coating of a water insoluble polymer and an enteric polymer; orally disintegrating tablets; storage stability
10/02/2008US20080241236 Minocycline oral dosage forms for the treatment of acne
10/02/2008US20080241235 Controlled release carrier selected from hydroxypropyl methyl cellulose, hydroxypropyl cellulose, and polyvinylpyrrolidone; improved pharmacokinetics as compared to immediate-release minocycline hydrochloride; side effect reduction
10/02/2008US20080241234 Preventing polymorphic conversion during preparation and storage of dosage form; ease of formulation; in vivo pharmacology; estrogen receptor modulation
10/02/2008US20080241233 In large unilamellar lipid vesicles containing phosphatidylserine, procoagulant phospholipid, proteins having binding affinity for collagen, human platelet glycoprotein Ib or Von Willebrands Factor, and a phospholipid scramblase; thrombocytopenia, chemotherapy, surgery or injury
10/02/2008US20080241232 Use of green porphyrins to treat neovasculature in the eye
10/02/2008US20080241231 Transdermal delivery of dexamethasone and promethazine
10/02/2008US20080241230 Method of Treating Scar Tissue
10/02/2008US20080241228 Polypeptide Films and Methods
10/02/2008US20080241227 Composition for Treating Dehydration in Large Mammals
10/02/2008US20080241226 Methods and Kits For Administering Probiotics
10/02/2008US20080241225 Soaking ionic lenses in a soluble silver salt solution, and then adding a salt precursor to give an insoluble silver salt, preferably silver iodide; haze-free
10/02/2008US20080241224 Non-Polymeric Lipophilic Pharmaceutical Implant Compositions For Intraocular Use
10/02/2008US20080241223 Implanting the extended release, biodegradable implant containing dexamethasone directly into the vitreous of the eye; side effect reduction; macular degeneration; angiogenesis inhibition
10/02/2008US20080241222 Implanting the extended release, biodegradable implant containing dexamethasone directly into the vitreous of the eye; side effect reduction; macular degeneration
10/02/2008US20080241221 Extended therapeutic effect ocular implant treatments
10/02/2008US20080241220 Extended therapeutic effect ocular implant treatments
10/02/2008US20080241219 Implanting the extended release, biodegradable implant containing dexamethasone directly into the vitreous of the eye; side effect reduction; macular degeneration
10/02/2008US20080241218 Intravascular stent having an iridium oxide, gold, platinum, titanium or inert carbon coating, and a number or reservoirs with an antibiotic, anticoagulant, antiproliferative, bactericide, angiogenesis inhibitor, growth factor, or radionuclide; greater control of drug placement and coating durability
10/02/2008US20080241216 Preparation Containing Active and/or Auxiliary Substances, With Controllable Release of Said Substances, As Well As Its Use and Manufacture
10/02/2008US20080241211 Carrier matrix having an osteoinductive agent selected from TGF- beta or a bone morphogenic protein, and an osteoinductive enhancer, preferably naringin, integrated therein; dentistry
10/02/2008US20080241210 Pro-angiogenic protein 156A, also called Angiodensine which stimulates migration of endothelial cells; use treating chronic or acute wounds
10/02/2008US20080241208 Methods, Compositions and Devices For Promoting Anglogenesis
10/02/2008US20080241206 Mixing kit components containing a setting fluid, dry calcium carbonate, oxide or hydroxide, dry phosphoric acid and bone particles, making a flowable, moldable mixture for orthopedics or dentistry
10/02/2008US20080241203 A biodegradable woven cloth, a nonwoven fabric, a sheet, or sponge having a surgical adhesion prevention layer; wound healing agents
10/02/2008US20080241199 "Micro-Patch" for Assessment of the Local Microvasculature and Microcirculatory Vasoreactivity
10/02/2008US20080241198 Selective angiogenesis and gene expression inhibition of the vascular endothelial growth factor pathway; ocular disease; antiarthritic, antiinflammatory agents
10/02/2008US20080241197 Minocycline dosage forms for the treatment of acne
10/02/2008US20080241120 Therapeutic mixturecomprising pilocarpine combined with bioadhesive polymer for use in treatment of reduced salivation
10/02/2008US20080241105 Pretreatment with oncolytic virus
10/02/2008US20080241097 Methods of treating neurological conditions with hematopoeitic growth factors
10/02/2008US20080241094 An oral dosage form containing a polymer that swells upon absorbing water from gastric fluid to increase its size thereby promoting its gastric retention, maintains its physical integrity in a stomach for at least 2 hours, and is degradable by an intestinal enzyme or exposure to an intestinal pH
10/02/2008US20080241093 A potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic
10/02/2008US20080241092 Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic
10/02/2008US20080241080 Composition for treating xerostomia or dry mouth
10/02/2008US20080241079 Skin Care Products
10/02/2008US20080241078 Compositions and methods for treating hair loss using c16-c20 aromatic tetrahydro prostaglandins
10/02/2008US20080241077 Benzoylguanidine salt and hydrates thereof
10/02/2008US20080241076 Administering orally a composition comprised of the omega 6 fatty acid, arachidonic acid, to increase red blood cells leading to an increase in tissue oxygenation and thus athletic endurance; includes nutrients vitamins, minerals, along with phosphate, herbs and natta kinase, a proteolytic enzyme
10/02/2008US20080241075 Parasite Vaccine
10/02/2008US20080241072 Injectable void filler for soft tissue augmentation
10/02/2008US20080241070 Fenofibrate dosage forms
10/02/2008US20080237905 Preparation of polyphosphazene microspheres
10/02/2008US20080237028 Nucleation in liquid, methods of use thereof and methods of generation thereof
10/02/2008US20080236579 Method for the administration of an anticholinergic by inhalation
10/02/2008DE102007015282A1 Viskositätsregulator, Verfahren zu dessen Herstellung und dessen Verwendung Viscosity regulator, a process for its preparation and its use
10/02/2008DE102007015044A1 Zusammensetzung zur topisch-dermalen Anwendung von homöopathischen Mitteln Composition for topical dermal application of homeopathic remedies
10/02/2008CA2687648A1 Topical dermal delivery device for nitric oxide delivery
10/02/2008CA2687640A1 Topical dermal delivery device for nitric oxide delivery
10/02/2008CA2684655A1 Oral pharmaceutical preparation for colon-specific delivery
10/02/2008CA2682490A1 Prompt nucleic acid delivery carrier composition
10/02/2008CA2682173A1 Solid fibrinogen preparation
10/02/2008CA2681591A1 Pulverized crystals of olmesartan medoxomil
10/02/2008CA2681514A1 Use of a masked or coated copper salt for the treatment of macular degeneration
10/02/2008CA2681465A1 Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
10/02/2008CA2680365A1 Coacervation process
10/02/2008CA2680106A1 Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
10/02/2008CA2679796A1 Capsule containing plant preparations
10/02/2008CA2678272A1 Use of ranolazine for the treatment of cardiovascular diseases
10/02/2008CA2583658A1 Multi-carotenoids compositions and uses therefor
10/01/2008EP1975172A2 High affinity TGFß nucleic acid ligands and inhibitors
10/01/2008EP1974751A1 Formulations for non-steroidal anti-inflammatory drugs
10/01/2008EP1974750A1 Preventive or therapeutic agent and method for immune disease
10/01/2008EP1974744A1 Immunization through oral administration of a vaccine with an edible product
10/01/2008EP1974741A1 Dried blood factor composition stabilised by trehalose
10/01/2008EP1974733A1 Use of a masked or coated copper salt for the treatment of macular degeneration
10/01/2008EP1974726A2 Matrix compositions for controlled delivery of drug substances
10/01/2008EP1974725A1 Sustained release preparation and method for production thereof
10/01/2008EP1974724A2 Oral preparations with good disintegration
10/01/2008EP1974723A2 Secure forms of anti-EGFR antibodies
10/01/2008EP1974722A2 Modified dosage forms of tacrolimus
10/01/2008EP1974721A1 Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles
10/01/2008EP1973837A2 Nanolipidic particles
10/01/2008EP1973601A2 Iontophoretic transdermal delivery of nicotine salts
10/01/2008EP1973570A1 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation
10/01/2008EP1973566A1 An adjuvant system comprising virosomes and liposomes
10/01/2008EP1973552A2 Parenteral nutrition composition containing iron
10/01/2008EP1973550A2 Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
10/01/2008EP1973533A2 Gastric reflux resistant dosage forms
10/01/2008EP1973532A1 Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
1 ... 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 ... 2991